Financials data is unavailable for this security.
View more
Year on year Dr Reddy's Laboratories Ltd grew revenues 13.54% from 246.70bn to 280.11bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 23.75% net income growth from 45.07bn to 55.78bn.
| Gross margin | 70.80% |
|---|---|
| Net profit margin | 19.22% |
| Operating margin | 22.78% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Dr Reddy's Laboratories Ltd increased its cash reserves by 22.98%, or 1.33bn. The company earned 45.43bn from its operations for a Cash Flow Margin of 16.22%. In addition the company used 40.28bn on investing activities and also paid 3.76bn in financing cash flows.
| Cash flow per share | 423.50 |
|---|---|
| Price/Cash flow per share | 15.64 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 23.52%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.71% |
|---|---|
| Div growth rate (5 year) | 14.87% |
| Payout ratio (TTM) | 11.99% |
| EPS growth(5 years) | 23.31 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 17.60 |
More ▼
